Measures for Conducting Comparative Benefit: Risk Assessment
暂无分享,去创建一个
Christy Chuang-Stein | Richard Entsuah | Yili Pritchett | C. Chuang-Stein | Y. Pritchett | R. Entsuah
[1] Stuart Walker,et al. A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model (vol 16, pg S16, 2007) , 2007 .
[2] R. Gelber,et al. Quality adjusted survival analysis. , 1990, Statistics in medicine.
[3] H. Korting,et al. The Benefit/Risk Ratio: A Handbook for the Rational Use of Potentially Hazardous Drugs , 1998 .
[4] J. Hutton,et al. Number needed to treat: properties and problems , 2000 .
[5] M Pirmohamed,et al. Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses? , 2007, Clinical pharmacology and therapeutics.
[6] R. Entsuah,et al. Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo , 2002, CNS Spectrums.
[7] C Chuang-Stein,et al. Organization and analysis of safety data using a multivariate approach. , 1992, Statistics in medicine.
[8] C Chuang-Stein,et al. A new proposal for benefit-less-risk analysis in clinical trials. , 1994, Controlled clinical trials.
[9] I. Bross. How to use Ridit Analysis , 1958 .
[10] Payne Jt,et al. A survey of the benefits and risks in the practice of radiology. , 1975 .
[11] Sam Salek,et al. A quantitative approach to benefit‐risk assessment of medicines – part 1: the development of a new model using multi‐criteria decision analysis , 2007, Pharmacoepidemiology and drug safety.
[12] J. Payne,et al. A survey of the benefits and risks in the practice of radiology. , 1975, CRC critical reviews in clinical radiology and nuclear medicine.
[13] Richard Entsuah,et al. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. , 2002, Journal of psychiatric research.
[14] E Lesaffre,et al. A note on the number needed to treat. , 1999, Controlled clinical trials.
[15] S. Walter,et al. Number needed to treat (NNT): estimation of a measure of clinical benefit , 2001, Statistics in medicine.
[16] H. Mouridsen,et al. Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Mary Cushman,et al. Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.
[18] J. Potter,et al. Risks and benefits of celecoxib to prevent recurrent adenomas. , 2006, The New England journal of medicine.
[19] Andrew P. Grieve,et al. The number needed to treat: a useful clinical measure or a case of the Emperor's new clothes? , 2003 .
[20] P. O'Brien. Procedures for comparing samples with multiple endpoints. , 1984, Biometrics.
[21] R. Temple. Quantitative Decision Analysis: A Work in Progress , 2007, Clinical pharmacology and therapeutics.
[22] H. Fineberg,et al. Risk-Benefit Considerations in the Management of Polymyalgia Rheumatica , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.
[23] Victor Kipnis,et al. Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative , 1996 .
[24] Sam Salek,et al. Retracted:A quantitative approach to benefit‐risk assessment of medicines — part 2: the practical application of a new model , 2007, Pharmacoepidemiology and drug safety.
[25] V. Hasselblad,et al. Placebo-Controls in Short-Term Clinical Trials of Hypertension , 2001, Science.
[26] Richard D. Gelber,et al. A quality-of-life-oriented endpoint for comparing therapies. , 1989 .
[27] Ingram Olkin,et al. Bias of estimates of the number needed to treat , 2005, Statistics in medicine.
[28] C Chuang-Stein,et al. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. , 1991, Statistics in medicine.